Research ExplorerPublicationsDiagnostic value of 18F-FDG-PET/CT for monitoring myelofibro...

Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation

Standard

Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. / Derlin, Thorsten; Büsche, Guntram; Kröger, Nicolaus.

In: NUCL MED REV, Vol. 18, No. 1, 11.02.2015, p. 35-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Derlin, T, Büsche, G & Kröger, N 2015, 'Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation', NUCL MED REV, vol. 18, no. 1, pp. 35-6. https://doi.org/10.5603/NMR.2015.0008

APA

Derlin, T., Büsche, G., & Kröger, N. (2015). Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. NUCL MED REV, 18(1), 35-6. https://doi.org/10.5603/NMR.2015.0008

Vancouver

Derlin T, Büsche G, Kröger N. Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. NUCL MED REV. 2015 Feb 11;18(1):35-6. https://doi.org/10.5603/NMR.2015.0008

Bibtex

@article{986830a80ac34808b091dbcdc2e9dec8,
title = "Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation",
abstract = "Myelofibrosis is a rare hematopoietic stem cell neoplasm leading to marked bone marrow fibrosis and ineffective hematopoiesis. We report a case highlighting the potential role of ¹⁸F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for therapy monitoring. A 62-year-old man with myelofibrosis underwent FDG-PET/CT for evaluation of the extent of disease before and after allogeneic stem cell transplantation (SCT). PET after SCT demonstrated complete normalization of initially increased bone marrow tracer uptake, consistent with bone marrow biopsy showing complete remission. ¹⁸F-FDG-PET/CT may become a valuable diagnostic tool in myelofibrosis, enabling both sensitive initial staging and therapy monitoring.",
author = "Thorsten Derlin and Guntram B{\"u}sche and Nicolaus Kr{\"o}ger",
year = "2015",
month = feb,
day = "11",
doi = "10.5603/NMR.2015.0008",
language = "English",
volume = "18",
pages = "35--6",
journal = "NUCL MED REV",
issn = "1506-9680",
publisher = "Via Medica",
number = "1",

}

RIS

TY - JOUR

T1 - Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation

AU - Derlin, Thorsten

AU - Büsche, Guntram

AU - Kröger, Nicolaus

PY - 2015/2/11

Y1 - 2015/2/11

N2 - Myelofibrosis is a rare hematopoietic stem cell neoplasm leading to marked bone marrow fibrosis and ineffective hematopoiesis. We report a case highlighting the potential role of ¹⁸F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for therapy monitoring. A 62-year-old man with myelofibrosis underwent FDG-PET/CT for evaluation of the extent of disease before and after allogeneic stem cell transplantation (SCT). PET after SCT demonstrated complete normalization of initially increased bone marrow tracer uptake, consistent with bone marrow biopsy showing complete remission. ¹⁸F-FDG-PET/CT may become a valuable diagnostic tool in myelofibrosis, enabling both sensitive initial staging and therapy monitoring.

AB - Myelofibrosis is a rare hematopoietic stem cell neoplasm leading to marked bone marrow fibrosis and ineffective hematopoiesis. We report a case highlighting the potential role of ¹⁸F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for therapy monitoring. A 62-year-old man with myelofibrosis underwent FDG-PET/CT for evaluation of the extent of disease before and after allogeneic stem cell transplantation (SCT). PET after SCT demonstrated complete normalization of initially increased bone marrow tracer uptake, consistent with bone marrow biopsy showing complete remission. ¹⁸F-FDG-PET/CT may become a valuable diagnostic tool in myelofibrosis, enabling both sensitive initial staging and therapy monitoring.

U2 - 10.5603/NMR.2015.0008

DO - 10.5603/NMR.2015.0008

M3 - SCORING: Journal article

C2 - 25633515

VL - 18

SP - 35

EP - 36

JO - NUCL MED REV

JF - NUCL MED REV

SN - 1506-9680

IS - 1

ER -